119 related articles for article (PubMed ID: 19433385)
21. Targeting bone microenvironment: Clinical implications.
Gnant M
Breast; 2015 Nov; 24 Suppl 2():S49-50. PubMed ID: 26238438
[No Abstract] [Full Text] [Related]
22. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
23. The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ..
Gnant M; Eidtmann H
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S2-6. PubMed ID: 20427029
[No Abstract] [Full Text] [Related]
24. Bone targeted therapies in early breast cancer.
Tabane K; Vorobiof DA
Curr Treat Options Oncol; 2011 Dec; 12(4):412-23. PubMed ID: 21887503
[TBL] [Abstract][Full Text] [Related]
25. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
26. Bone health after diagnosis of breast cancer.
Ruzycki SM; Nixon NA
CMAJ; 2018 Dec; 190(49):E1452. PubMed ID: 30530612
[No Abstract] [Full Text] [Related]
27. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates for breast cancer: questions answered, questions remaining.
Layman R; Olson K; Van Poznak C
Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
[TBL] [Abstract][Full Text] [Related]
29. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Brufsky AM
Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant bisphosphonates for early-stage breast cancer.
Brufsky A
Lancet Oncol; 2011 Jul; 12(7):610-1. PubMed ID: 21708345
[No Abstract] [Full Text] [Related]
31. The effect of aromatase inhibitors on bone metabolism.
Folkestad L; Bjarnason NH; Bjerregaard JK; Brixen K
Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547
[TBL] [Abstract][Full Text] [Related]
32. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
Lein M; Miller K; Wirth M; Weissbach L; May C; Schmidt K; Haus U; Schrader M; Jung K
Prostate; 2009 May; 69(6):624-32. PubMed ID: 19143027
[TBL] [Abstract][Full Text] [Related]
33. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
[TBL] [Abstract][Full Text] [Related]
34. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates as adjuvant therapy.
Shapiro CL
Clin Adv Hematol Oncol; 2009 May; 7(5):319-20. PubMed ID: 19521319
[No Abstract] [Full Text] [Related]
36. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
37. Advances in management of bone disease in breast cancer.
Walkington L; Coleman RE
Bone; 2011 Jan; 48(1):80-7. PubMed ID: 20621652
[TBL] [Abstract][Full Text] [Related]
38. [Integrated supportive therapy for multiple myeloma-bone disease treatment, myeloma kidney treatment, cryotherapy, nutrition support team].
Miwa A
Nihon Rinsho; 2012 Apr; 70 Suppl 2():603-27. PubMed ID: 23134022
[No Abstract] [Full Text] [Related]
39. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
Syversen U; Halse JI
Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
Aft R
Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]